AstraZeneca Return On Equity from 2010 to 2024
| AZN Stock | USD 75.17 0.14 0.19% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 0.15213448 | Current Value 0.14 | Quarterly Volatility 0.18068122 |
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many exotic indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0285 or PTB Ratio of 9.53. AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
AstraZeneca | Return On Equity |
Latest AstraZeneca PLC's Return On Equity Growth Pattern
Below is the plot of the Return On Equity of AstraZeneca PLC ADR over the last few years. Return on Equity is the amount of AstraZeneca PLC ADR net income returned as a percentage of AstraZeneca PLC equity. Return on equity measures AstraZeneca PLC profitability by revealing how much profit AstraZeneca PLC ADR generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. AstraZeneca PLC's Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AstraZeneca PLC's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.17 | 10 Years Trend |
|
Return On Equity |
| Timeline |
AstraZeneca Return On Equity Regression Statistics
| Arithmetic Mean | 0.20 | |
| Geometric Mean | 0.13 | |
| Coefficient Of Variation | 88.30 | |
| Mean Deviation | 0.11 | |
| Median | 0.15 | |
| Standard Deviation | 0.18 | |
| Sample Variance | 0.03 | |
| Range | 0.7471 | |
| R-Value | (0.62) | |
| Mean Square Error | 0.02 | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (0.02) | |
| Total Sum of Squares | 0.46 |
AstraZeneca Return On Equity History
About AstraZeneca PLC Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include AstraZeneca PLC income statement, its balance sheet, and the statement of cash flows. AstraZeneca PLC investors use historical funamental indicators, such as AstraZeneca PLC's Return On Equity, to determine how well the company is positioned to perform in the future. Although AstraZeneca PLC investors may use each financial statement separately, they are all related. The changes in AstraZeneca PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AstraZeneca PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on AstraZeneca PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in AstraZeneca PLC. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 0.15 | 0.14 |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
| 0.63 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
Moving against AstraZeneca Stock
| 0.68 | INTC | Intel Financial Report 25th of July 2024 | PairCorr |
| 0.56 | MCD | McDonalds Financial Report 25th of July 2024 | PairCorr |
| 0.49 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
| 0.41 | HD | Home Depot Financial Report 21st of May 2024 | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of AstraZeneca PLC Correlation against competitors. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.207 | Dividend Share 2.9 | Earnings Share 2.02 | Revenue Per Share 2.5512 | Quarterly Revenue Growth 0.165 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.